# Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)

> **NCT01679990** · PHASE2 · COMPLETED · sponsor: **Pluristem Ltd.** · enrollment: 180 (actual)

## Conditions studied

- Intermittent Claudication
- Peripheral Artery Disease

## Interventions

- **BIOLOGICAL:** PLX-PAD Low dose
- **BIOLOGICAL:** PLX-PAD high doses
- **BIOLOGICAL:** Double Placebo
- **BIOLOGICAL:** high dose +Placebo

## Key facts

- **NCT ID:** NCT01679990
- **Lead sponsor:** Pluristem Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-05
- **Primary completion:** 2018-03-29
- **Final completion:** 2019-02-09
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2019-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01679990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01679990, "Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01679990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*